A breakthrough drug for treating the most common type of lung cancer was just approved by the Food and Drug Administration ahead of schedule following two successful clinical trials, including one that involved patients at Providence Cancer Center in Portland.
Cancer patients in Oregon, Washington and three other Western states will receive improved access to care and clinical trials as a result of a new $6.6 million grant from the National Cancer Institute’s Community Oncology Research Program, or NCORP.
Previously reserved for researchers and the very rich, a next generation technique aims to improve treatment and outcomes for patients at the clinical level.
In a significant show of support for immunotherapy research in the treatment of cancer, the National Institutes of Health has awarded a $1.6...
Ellen Patterson spent her summer as a cancer research intern at Providence Cancer Center after successfully battling ovarian cancer at 15.
Finding effective treatments for the various types of cancer – it’s the goal of researchers around the world, and right here in Portland. Now Providence Cancer Center is the first site in the nation to test a new immunotherapy treatment that’s showing great promise for patients fighting B-cell non-Hodgkin’s lymphoma and chronic lymphocytic leukemia.
The donation is a result of the store chain's third quarter employee giving campaign and all the coins collected in the checkout lines at Portland area locations.
Dr. Walter Urba, director of cancer research for Providence's Robert W. Franz Cancer Research Center, comments on experimental immunotherapy treatment in this article from The Bend Bulletin.
Patients with advanced melanoma are getting a boost from work being done at Providence, thanks to a grant from the National Institutes of Health.
In the past 20 years, Providence has contributed to several significant breakthroughs in cancer research.
Providence's involvement with the International Immuno-Oncology Network, along with other early-phase studies, is broadening treatment options for patients with advanced cancers.
Funds from Safeway's "round up" at the checkout counters will be divided among four areas of breast cancer research at Providence.
Research scientist Keith Bahjat, Ph.D., recently received two grants supporting work on immunotherapy.
Providence is the only cancer facility in Oregon to receive QOPI certification.
Bernie Fox, Ph.D., speaks at annual meeting in China about a new approach to determine immune response to tumors.
Read about this and more in Providence Cancer Center's summer clinical newsletter.
Providence Cancer Center researchers study a unique approach, combining radiation and immunotherapy treatments.
"There is still a long road ahead, but now it's lined with some successes," says Walter Urba, M.D., Ph.D.
Safeway customers and employees in Oregon and Southwest Washington raised $500,000 for breast cancer awareness, treatment and research at Providence.
Read the latest highlights on our researchers.
Providence Cancer Center researcher Michael Gough, Ph.D., has received a Career Catalyst Research Grant from Susan G. Komen for the Cure to study the possibility of ending metastatic cancer.
The biotech company will fund further OX40 research developed by Providence scientists.
William Redmond, Ph.D., received the 2011 V Scholar Award from The V Foundation for Cancer Research.
Ipilimumab is the first drug shown to extend survival in patients with late-stage melanoma.